{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-018636","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2025-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.003755+00:00","generated_at":"2026-05-25T22:42:56.844024+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Traws Pharma regains Nasdaq compliance with $2.5M equity rule; under monitoring until Feb 2026","bullets":["Received Nasdaq confirmation on Feb 25, 2025 of compliance with minimum $2.5M stockholders' equity requirement.","Subject to mandatory panel monitoring through Feb 25, 2026; future non-compliance may lead to delisting without cure period.","Closed $20M gross proceeds offering on Dec 30, 2024 to strengthen financial position.","CEO cites potential transformational year ahead with bird flu/influenza antiviral pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-018636","json":"https://secwatch.observer/filing/0001104659-25-018636.json","markdown":"https://secwatch.observer/filing/0001104659-25-018636.md","text":"https://secwatch.observer/filing/0001104659-25-018636.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925018636/0001104659-25-018636-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925018636/tm257866d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T22:42:56.844024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}